Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma

Eye

Volumn 14, Issue 1, 2000, Pages 73-77

  Konstas, Anastasios G P ^a   Maltezos, Athanasios ^a   Bufidis, Theodoros ^a   Hudgins, Alison G ^b   Stewart, William C ^b,c  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b University of South Carolina   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dorzolamide; Exfoliation glaucoma; Primary open angle glaucoma; Timolol maleate

Indexed keywords

DORZOLAMIDE; TIMOLOL MALEATE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRY EYE; EXFOLIATION SYNDROME; EYE BURN; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; TASTE DISORDER; VISUAL IMPAIRMENT;

EID: 0034096208     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.2000.16     Document Type: Article

References (23)

1. Konstas AGP, Stewart WC, Stroman GA, et al. Clinical presentation and initial treatment patterns in patients with exfoliation versus primary open-angle glaucoma. Ophthalmic Surg Lasers 1997;28:111-7.
2. Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:182-5.
3. Konstas AGP, Mantziris DA, Gate EA, et al. Effect of timolol on the diurnal IOP in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:975-9.
4. Book SA. Essentials of statistics. New York: McGraw Hill, 1978:117-22, 205-15.
5. Stewart WC, Gate EA, Pruitt CA. Additivity of latanoprost 0.0005% to timolol hemihydrate 0.5% in ocular hypertensive or chronic open-angle glaucoma patients. Ciba Vision Ophthalmics internal report, 1997.
6. 1-adrenergic antagonist. Am J Ophthalmol 1985;100:777-82.
7. Moses L, Emerson J, Hosseini H. Statistics in practice: analysing data from ordered categories. N Engl J Med 1984;311:442-8.
8. Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol 1991;109:1297-9.
9. Wayman LL, Larsson L-I, Maus TL, Brubaker RF. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Arch Ophthalmol 1998;116:1438-40.
10. Larrson L-I, Ahn A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol 1998;116:19-24.
11. Wayman L, Larsson L-I, Maus T, Alm A, Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:1368-71.
12. Maus TL, Larsson L-I, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:45-9.
13. Vanlandingham BD, Maus TL, Brubaker RF. The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep. Ophthalmology 1998;105:1537-40.
14. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495-9.
15. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-13.
16. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111:1343-50.
17. Kitazawa Y, Azuma I, Iwata K, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994;3:275-9.
18. Strahlman E, Tipping R, Vogel R, et al. A double masked, randomized one-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995;113:1009-16.
19. Nardin G, Lewis R, Lippa EA, Keates E, Coleman A, Clineschmidt Panebianco D, et al. Activity of the topical CAI MK-507 bid when added to timolol bid. Invest Ophthalmol Vis Sci 1991;32(Suppl):989.
20. Strahlman ER, Vogel R, Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996;103:1283-93.
21. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation glaucoma or ocular hypertension. Ophthalmology 1997;104:137-412.
22. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985;26(Suppl):1315-9.
23. Stewart WC. Current and future glaucoma therapy. Ciba Vision Ophthalmics Clinical Symposium, 1997:1-43.